WorldCat Identities

Shapiro, Charles L.

Overview
Works: 4 works in 15 publications in 1 language and 70 library holdings
Roles: Editor
Publication Timeline
.
Most widely held works by Charles L Shapiro
New directions in breast cancer : research and therapeutics( Book )

4 editions published in 1994 in English and held by 48 WorldCat member libraries worldwide

New directions in breast cancer research and therapeutics( Book )

4 editions published in 1994 in English and held by 11 WorldCat member libraries worldwide

Late effects of treatment and survivorship issues in early-stage breast carcinoma( Book )

2 editions published in 2003 in English and held by 5 WorldCat member libraries worldwide

The Effect of Cox-2 Inhibitors on the Aromatase Gene (CYP19) Expression in Human Breast Cancer( Book )

5 editions published between 2002 and 2006 in English and held by 2 WorldCat member libraries worldwide

Aromatase (CYP-l9) is responsible for estrogen biosynthesis within breast tumor tissue. Aromatase and cyclooxygenase-2 (COX-2) are both overexpressed in human breast cancer, and increased levels of prostaglandin (PG) activates the CYP19 promotor and increases gene expression. We hypothesize that celecoxib, a selective COX-2 inhibitor, will decrease PG, decrease the expression of CYPl9, and reduce estrogen biosynthesis within tumor tissue. To test this hypothesis, in DOD grant # DAMD17-C-01-0589, tumor tissue will be collected from breast cancer patients at the initial diagnosis, and again at the definitive surgery (lumpectomy or mastectomy) for breast cancer. In the 10-14 day interval before the definitive surgery, patients will receive celecoxib and tissue samples collected before and after treatment with celecoxib will be evaluated for gene expression of COX-2 and CYPl9. If our hypothesis is correct, then expression of the CYPl9 gene will decrease in response to celecoxib. This study will provide preliminary data to a) support a mechanism whereby COX-2 inhibitors decrease estrogen production within breast tumors by decreasing CYP19 expression; and b) provide the rationale for initiating larger chemoprevention and therapeutic trials of COX-2 inhibitors in high risk and breast cancer patients
 
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.70 (from 0.64 for New direct ... to 0.95 for The Effect ...)

Associated Subjects
Languages
English (15)